Targeting GFPT2 to reinvigorate immunotherapy in EGFR-mutated NSCLC
L. Ao, W. Jia, Q. Gong, J. Cui, J. Wang, Y. Yu, C. Fu, H. Li, J. Wei, R. Wang, F. Wang, X. Shang, Y. Li, S. Fang, G. Wang, , J. Liu
This study identifies GFPT2 as a metabolic checkpoint in EGFR-mutated NSCLC that promotes immune evasion, and shows that targeting GFPT2 enhances PD-1 blockade therapy.
bioRxiv · Mar 1, 2024 · PreprintCancer Biology